Efficacy and toxicity evaluation
Response was defined as the best observed response after at least one cycle of Doxorubicin Hydrochloride Liposome plus irinotecan regimen. According to the RECIST (Response Evaluation Criteria of Solid Tumors) standard for efficacy evaluation, it is divided into: complete response (CR), partial response (PR), stable (SD) and progression (PD). Progression Free Survival (PFS) is defined as the time from the start of the Doxorubicin Hydrochloride Liposome plus irinotecan regimen to the progression of the disease or the time of the last follow-up. Overall Survival (OS) is defined as the time from the start of the Doxorubicin Hydrochloride Liposome plus irinotecan regimen to death or the last follow-up.
Toxicity assessment is based on the Common Terminology Criteria for Adverse Events (CTCAE 4.03).